---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-048184"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:49:20.157483+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Senti Biosciences raises up to $47.6M in Series A preferred stock and warrants private placement

## Summary
- Issued up to 21,157 shares of Series A Convertible Preferred at $2,250/share, with warrants for up to 31.7M common shares at $2.30.
- Initial closing of $37.6M (16,713 preferred shares) expected Dec 5, 2024; option for additional $9.9M by Dec 27, 2024.
- Series A Preferred carries 18% annual cumulative dividend, convertible into common at $2.25 after stockholder approval.
- Director Omid Farokhzad resigned; Frances Schulz (former EY partner) and Donald Tang (Celadon designee) appointed to board.
- Net proceeds to fund working capital, R&D, and SENTI-202 program advancement.

## SEC filing metadata
- accession: 0001140361-24-048184
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 5.03, 2.03, 3.02, 3.03, 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/ef20039400_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-048184
- JSON: https://secwatch.observer/filing/0001140361-24-048184.json
- Plain text: https://secwatch.observer/filing/0001140361-24-048184.txt

## Key facts
- Executive change
  Frances D. Schulz was appointed as Director at Senti Biosciences, Inc..
  - Action: appointed
  - Role: Director
  source text: On December 2, 2024, upon the recommendation of its Nominating and Corporate Governance Committee, the Board unanimously appointed Frances D. Schulz to fill a newly created vacancy on the Board resulting from the resignation of Dr. Farokhzad, such appointment to be effective upon the initial closing of the Offering.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm
- Executive change
  Omid Farokhzad resigned as Director at Senti Biosciences, Inc..
  - Action: resigned
  - Role: Director
  source text: On November 25, 2024, Omid Farokhzad, M.D., a member of the Board and the Audit Committee of the Board, notified the Board of his resignation as a director of the Company and all committees thereof, effective November 25, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048184/0001140361-24-048184-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.